Preclinical pharmacokinetics and metabolism study of SCO-267, a GPR40 full agonist, in beagle dogs using ultra-high performance liquid chromatography coupled to tandem mass spectrometry
- PMID:37189222
- DOI: 10.1002/bmc.5685
Preclinical pharmacokinetics and metabolism study of SCO-267, a GPR40 full agonist, in beagle dogs using ultra-high performance liquid chromatography coupled to tandem mass spectrometry
Abstract
SCO-267 is a GPR40 full agonist that has been developed for the treatment of diabetes. To support its preclinical and clinical development, in this study, we developed an ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of SCO-267 in dog plasma using cabozantinib as internal standard (IS). The chromatographic separation was obtained on a Waters acquity BEH C18 column (50 × 2.1 mm, i.d., 1.7 μm) and the detection was performed using Thermo TSQ triple quadrupole mass spectrometer with multiple reaction monitoring positive mode at m/z 615.3 > 230.1 for SCO-267 and m/z 502.5 > 323.3 for IS. The method was validated over the concentration range of 1-2,000 ng/ml with the lower limit of quantification of 1 ng/ml. The selectivity, linearity, precision and accuracy over this range were acceptable. The extraction recovery was more than 88.73% and no matrix effect was observed. SCO-267 was demonstrated to be stable during the storage and processing period. The new method was successfully applied to the pharmacokinetic study in beagle dogs following a single oral and intravenous administration. The oral bioavailability was 64.34%. In addition, the metabolites from dog liver microsomal incubation and plasma collected after an oral administration were identified by a UHPLC-HRMS method. The biotransformation pathways of SCO-267 involved oxygenation, O-demethylation, N-dealkylation and acyl glucuronidation.
Keywords: SCO-267; UHPLC-MS/MS; bioavailability; metabolism; pharmacokinetics.
© 2023 John Wiley & Sons Ltd.
Similar articles
- Pharmacokinetic and bioavailability study of kurarinone in dog plasma by UHPLC-MS/MS.Huang Y, Lin H, Chen Y, Huang X.Huang Y, et al.Biomed Chromatogr. 2020 Nov;34(11):e4945. doi: 10.1002/bmc.4945. Epub 2020 Jul 19.Biomed Chromatogr. 2020.PMID:32656774
- Application of newly developed and validated UPLC-MS/MS method for pharmacokinetic study of ROS1/NTRK inhibitor taletrectinib in beagle dog plasma.Zhu Y, Wang F, Wang X, Cheng Y, Wang X, Fan A, Chang J.Zhu Y, et al.J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Oct 15;1247:124305. doi: 10.1016/j.jchromb.2024.124305. Epub 2024 Sep 14.J Chromatogr B Analyt Technol Biomed Life Sci. 2024.PMID:39293159
- Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study.Wang MJ, Zhao YH, Fan C, Wang YJ, Wang XQ, Qiu XJ, Shen RL.Wang MJ, et al.Drug Des Devel Ther. 2021 Oct 2;15:4167-4175. doi: 10.2147/DDDT.S332282. eCollection 2021.Drug Des Devel Ther. 2021.PMID:34629864Free PMC article.
- Pharmacokinetics, bioavailability and metabolism of scopoletin in dog by ultra-high-performance liquid chromatography combined with linear ion trap-Orbitrap tandem mass spectrometry.Zhao YX, Wang M, Dong WT, Li Y.Zhao YX, et al.Biomed Chromatogr. 2019 Mar;33(3):e4436. doi: 10.1002/bmc.4436. Epub 2018 Nov 28.Biomed Chromatogr. 2019.PMID:30421792
- An ultra-high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous quantitation of 10 alkaloids of Corydalis Decumbentis Rhizoma preparation in dog plasma and its application to a pharmacokinetic study.Yu Y, Sun J, Yang C, Dong H, Wang Z, Wang Z.Yu Y, et al.Basic Clin Pharmacol Toxicol. 2023 Jan;132(1):33-50. doi: 10.1111/bcpt.13809. Epub 2022 Nov 11.Basic Clin Pharmacol Toxicol. 2023.PMID:36303263
References
REFERENCES
- Briscoe, C. P., Tadayyon, M., Andrews, J. L., Benson, W. G., Chambers, J. K., Eilert, M. M., Ellis, C., Elshourbagy, N. A., Goetz, A. S., Minnick, D. T., Murdock, P. R., Sauls, H. R. Jr., Shabon, U., Spinage, L. D., Strum, J. C., Szekeres, P. G., Tan, K. B., Way, J. M., Ignar, D. M., … Muir, A. I. (2003). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. The Journal of Biological Chemistry, 278(13), 11303-11311.https://doi.org/10.1074/jbc.M211495200
- Furukawa, H., Miyamoto, Y., Hirata, Y., Watanabe, K., Hitomi, Y., Yoshitomi, Y., Aida, J., Noguchi, N., Takakura, N., Takami, K., Miwatashi, S., Hirozane, Y., Hamada, T., Ito, R., Ookawara, M., Moritoh, Y., Watanabe, M., & Maekawa, T. (2020). Design and identification of a GPR40 full agonist (SCO-267) possessing a 2-carbamoylphenyl piperidine moiety. Journal of Medicinal Chemistry, 63(18), 10352-10379.https://doi.org/10.1021/acs.jmedchem.0c00843
- Hop, C. E., Wang, Z., Chen, Q., & Kwei, G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. Journal of Pharmaceutical Sciences, 87(7), 901-903.https://doi.org/10.1021/js970486q
- Hotha, K. K., Bharathi, D. V., Kumar, S. S., Reddy, Y. N., Chatki, P. K., Ravindranath, L. K., & Jayaveera, K. N. (2010). Determination of the quaternary ammonium compound trospium in human plasma by LC-MS/MS: Application to a pharmacokinetic study. Journal of Chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 878(13-14), 981-986.https://doi.org/10.1016/j.jchromb.2010.02.028
- Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., Tanaka, H., Maruyama, M., Satoh, R., Okubo, S., Kizawa, H., Komatsu, H., Matsumura, F., Noguchi, Y., Shinohara, T., … Fujino, M. (2003). Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. Nature, 422(6928), 173-176.https://doi.org/10.1038/nature01478
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources